Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from 18 analysts (14 buy, 1 strong buy, 2 hold, 1 sell) with an average 12‑month price target of $61.18.
• Insiders have sold 109,556 shares totaling $2.49M in the last 90 days — including CEO Emil Kakkis (54,404 shares) — leaving insiders with about 5.20% ownership.
• Latest quarter: EPS missed at ($1.29) vs. ($1.20) expected while revenue beat at $207.3M (+25.5% YoY); the company has a $2.41B market cap and analysts expect ~-4.49 EPS for the year.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eighteen research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $61.1765.

A number of brokerages have recently issued reports on RARE. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a "buy" rating on the stock in a research note on Wednesday, February 18th. Morgan Stanley lifted their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an "overweight" rating in a research report on Thursday, April 16th. Robert W. Baird reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 30th. Bank of America reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, January 2nd. Finally, Weiss Ratings downgraded Ultragenyx Pharmaceutical from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday.

Insider Activity

In related news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the transaction, the chief executive officer owned 658,994 shares in the company, valued at approximately $15,025,063.20. This trade represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the transaction, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 109,556 shares of company stock valued at $2,490,138 in the last 90 days. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC lifted its position in Ultragenyx Pharmaceutical by 79.1% during the third quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company's stock worth $5,759,000 after buying an additional 84,559 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $3,773,000. Aberdeen Group plc raised its position in Ultragenyx Pharmaceutical by 94.3% in the third quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company's stock valued at $29,288,000 after purchasing an additional 472,600 shares during the period. WCM Investment Management LLC raised its position in Ultragenyx Pharmaceutical by 36.9% in the third quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company's stock valued at $8,747,000 after purchasing an additional 77,640 shares during the period. Finally, Thornburg Investment Management Inc. purchased a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $2,083,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $24.53 on Wednesday. The business's 50 day moving average price is $22.37 and its 200-day moving average price is $27.06. The firm has a market capitalization of $2.41 billion, a PE ratio of -4.20 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business's revenue was up 25.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.39) earnings per share. As a group, analysts expect that Ultragenyx Pharmaceutical will post -4.49 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.